SEC Form 4 · accession 0000904454-18-000136
Paratek Pharmaceuticals, Inc. · PRTK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Adam Woodrow
Officer — VP & Chief Commercial Officer
Period of report
Feb 5, 2018
Accepted (ET)
Feb 7, 2018 · 6:20 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178711
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Feb 5, 2018 | S | 3,333 | $14.22 | D | 62,367 | D | |
| Common StockF1,F3 | Feb 6, 2018 | S | 11,000 | $13.77 | D | 51,367 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.43, inclusive. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.70 to $13.95, inclusive. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.